Oracle, AstraZeneca Partner to Use AI in Clinical Trials
The companies will explore AI-based tools to improve patient recruitment, clinical research and disease management, starting with a hypertension project in Abu Dhabi.
Topics
News
- External Review Finds Flaws in OpenAI’s Agent Monitoring System
- Microsoft AI System Outperforms General Physicians in Diagnostic Tests
- How Sundar Pichai Uses AI Agents to Track Google Operations
- Tech Mahindra Partners With SpaceXSI to Scale AI-Powered Coding
- Barclays to Cut 5,000 Jobs as AI Drives Cost Savings
- CERT-In Warns of Compromised eMudhra Certificate Authority Keys
[Image source: Krishna Prasad/MITSMR Middle East]
Oracle and AstraZeneca have announced a collaboration to explore using artificial intelligence and healthcare data to identify eligible patients for clinical trials and accelerate medical research.
Under a non-binding agreement announced Tuesday, the companies will combine AstraZeneca’s scientific expertise with Oracle’s cloud, AI, analytics and healthcare data capabilities to improve patient recruitment and bring research findings into clinical care.
The collaboration will cover cancer, cardiovascular, renal and metabolic diseases, respiratory and immune conditions, and rare diseases.
The first project, in partnership with Abu Dhabi healthcare company M42, will focus on identifying patients with uncontrolled hypertension, improving their care and supporting recruitment for clinical trials.
“Combining AstraZeneca’s world-class science with Oracle’s deep data and technology expertise, we can help clinicians identify patients sooner, optimize clinical trials, and generate evidence continuously across the lifecycle of a medicine,” said Pascal Soriot, CEO of AstraZeneca.
Oracle CEO Mike Sicilia said the collaboration could help translate scientific innovation into better patient outcomes by connecting more people to clinical trials and accelerating research.
The companies also plan to examine how data from clinical trials and routine healthcare can improve future study designs, drug-safety monitoring and treatment decisions.
The collaboration is expected to involve projects in the US, Middle East and Europe. The companies will establish shared governance arrangements and measures to assess results before deciding whether to expand successful approaches.
The agreement remains exploratory, with no commercial rollout announced.
The Oracle collaboration follows another AI-focused move by AstraZeneca. On October 15, the pharmaceutical company announced a strategic drug discovery collaboration and licensing agreement with insitro, an AI therapeutics company.
This is to identify potential drug targets and develop new treatments for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. Both conditions involve complex disease mechanisms and significant unmet medical needs.
Under the separate agreement, insitro will receive $40 million upfront and could earn up to approximately $1.46 billion in development and commercial milestone payments, along with royalties.
